Terns Pharmaceuticals Inc. (TERN) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Terns Pharmaceuticals Inc... (TERN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

4.58

-0.22 (-4.58%)

At close: Jan 14, 2025, 3:59 PM

4.69

2.51%

Pre-market Jan 15, 2025, 08:29 AM EST

undefined% (undefined)

Bid	4.65
Market Cap	388.60M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.18
PE Ratio (ttm)	-3.88
Forward PE	n/a
Analyst	Buy

Ask	4.87
Volume	1,248,560
Avg. Volume (20D)	1,623,885
Open	4.83
Previous Close	4.80
Day's Range	4.56 - 4.90
52-Week Range	4.32 - 11.40
Beta	undefined

About TERN

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 5, 2021

Employees 66

Stock Exchange NASDAQ

Ticker Symbol TERN

Website https://www.ternspharma.com

Analyst Forecast

According to 5 analyst ratings, the average rating for TERN stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 337.16% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

4 months ago · Source

-4.9%

Terns Pharmaceuticals shares are trading lower aft... Unlock content with Pro Subscription

4 months ago · Source

+23.14%

Terns Pharmaceuticals shares are trading higher after JMP Securities raised its price target on the stock from $15 to $20.

News

1 month ago · marketwatch.com

Terns's stock soars as analysts cheer leukemia data — and predict more gains

The pharma company now has two positive proof-of-concept trials under its belt, including its weight-loss pill.

1 month ago · https://thefly.com

Terns Pharmaceuticals price target raised to $20 from $17 at Oppenheimer

Oppenheimer raised the firm's price target on Terns Pharmaceuticals to $20 from $17 and keeps an Outperform rating on the shares. Terns reported an interim update on TERN-701's Phase 1 study in chroni...

1 month ago · marketwatch.com

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

Terns Pharmaceuticals Inc.'s stock jumped 7.5% premarket Tuesday, after the company announced positive data from an early-stage trial of a treatment for chronic myeloid leukemia.